Clinical Trial Update: Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trials evaluated the efficacy, safety, pharmacodynamics, and pharmacokinetics of olipudase alfa in patients with acid sphingomyelinase deficiency, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acid Sphingomyelinase Deficiency
• Niemann-pick Disease Type

Drugs mentioned

• Olipudase alfa (olipudase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Sphingomyelin Lipidosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2022-05-24